1Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Korea
2Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Korea
3Veterans Medical Research Institute, Veterans Health Service Medical Center, Seoul, Korea
Copyright © 2021 The Korean Society for Preventive Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
CONFLICT OF INTEREST
The authors have no conflicts of interest associated with the material presented in this paper.
FUNDING
This work was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (grant No. 2019R1A2C1004966 and 2020R1A2C1102097). This research was also funded by the Education and Research Encouragement Fund of Seoul National University Hospital.
AUTHOR CONTRIBUTIONS
Conceptualization: DH, Data curation: JYM, KBM. Formal analysis: DH, JYM, KBM. Funding acquisition: KBM. Methodology: DH, JYM, KBM. Project administration: KBM. Visualization: DH, JYM. Writing – original draft: DH. Writing – review & editing: DH, JYM, KBM.
Variables1 | Model 1 | p-value | Model 2 | p-value | Model 3 | p-value | Model 4 | p-value | Model 5 | p-value | |
---|---|---|---|---|---|---|---|---|---|---|---|
ALT (n = 11 818) | 0.005±0.007 | 0.435 | |||||||||
Volume-based model | - | 0.049±0.008 | <0.001 | 0.042±0.008 | <0.001 | 0.035±0.008 | <0.001 | 0.059±0.010 | <0.001 | ||
Creatinine-adjusted model | - | 0.066±0.008 | <0.001 | 0.056±0.008 | <0.001 | 0.051±0.008 | <0.001 | 0.074±0.010 | <0.001 | ||
AST (n = 11 818) | 0.020±0.005 | <0.001 | |||||||||
Volume-based model | - | 0.030±0.006 | <0.001 | 0.024±0.006 | <0.001 | 0.017±0.006 | 0.009 | 0.033±0.008 | <0.001 | ||
Creatinine-adjusted model | - | 0.045±0.007 | <0.001 | 0.037±0.007 | <0.001 | 0.029±0.007 | <0.001 | 0.044±0.008 | <0.001 | ||
GGT (n = 11 838) | 0.096±0.008 | <0.001 | |||||||||
Volume-based model | - | 0.093±0.011 | <0.001 | 0.084±0.011 | <0.001 | 0.070±0.011 | <0.001 | 0.071±0.013 | <0.001 | ||
Creatinine-adjusted model | - | 0.113±0.012 | <0.001 | 0.101±0.012 | <0.001 | 0.086±0.012 | <0.001 | 0.083±0.014 | <0.001 | ||
TB (n = 10 556) | 0.007±0.008 | 0.367 | |||||||||
Volume-based model | - | 0.034±0.009 | <0.001 | 0.034±0.009 | <0.001 | 0.041±0.010 | <0.001 | 0.080±0.013 | <0.001 | ||
Creatinine-adjusted model | - | 0.040±0.009 | <0.001 | 0.040±0.009 | <0.001 | 0.047±0.010 | <0.001 | 0.085±0.013 | <0.001 | ||
ALP (n = 10 564) | 0.045±0.004 | <0.001 | |||||||||
Volume-based model | - | 0.040±0.005 | <0.001 | 0.039±0.005 | <0.001 | 0.037±0.006 | <0.001 | 0.026±0.009 | 0.004 | ||
Creatinine-adjusted model | - | 0.049±0.006 | <0.001 | 0.048±0.006 | <0.001 | 0.047±0.007 | <0.001 | 0.030±0.009 | <0.001 |
Values are presented as beta±standard error.
Model 1: Not adjusted for any covariates; Model 2: Adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI; Model 3: Adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, BMI, HBV infection, HCV infection, and heavy drinking; Model 4: Excluded HBV-infected participants, HCV-infected participants, and heavy drinkers from the original study population and adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI; Model 5: Excluded smokers and former smokers from the original study population and adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; TB, total bilirubin; ALP, alkaline phosphatase; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus.
1 The sizes of subsamples used in models 1, 2, and 3 were indicated. The number of participants used in model 4 and 5 was different as follows: for model 4, the numbers of participants used to analyze the effect of cadmium on ALT, AST, GGT, TB, and ALP were 9928, 9928, 9944, 8843, and 8847, respectively; for model 5, the numbers of participants used to analyze the effect of cadmium on ALT, AST, GGT, TB, and ALP were 6174, 6174, 6184, 5545, and 5547, respectively.
Variables1 | Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |
---|---|---|---|---|---|---|
ALT (n = 11 818) | 1.138 (1.054, 1.230) | |||||
Volume-based model | 1.360 (1.210, 1.528) | 1.310 (1.163, 1.477) | 1.242 (1.090, 1.415) | 1.401 (1.181, 1.662) | ||
Creatinine-adjusted model | 1.430 (1.268, 1.614) | 1.361 (1.204, 1.539) | 1.311 (1.148, 1.496) | 1.417 (1.194, 1.681) | ||
AST (n = 11 818) | 1.179 (1.083, 1.283) | |||||
Volume-based model | 1.307 (1.149, 1.486) | 1.254 (1.096, 1.435) | 1.211 (1.042, 1.408) | 1.299 (1.095, 1.540) | ||
Creatinine-adjusted model | 1.396 (1.218, 1.601) | 1.322 (1.148, 1.522) | 1.271 (1.088, 1.485) | 1.367 (1.162, 1.609) | ||
GGT (n = 11 838) | 1.479 (1.369, 1.598) | |||||
Volume-based model | 1.520 (1.357, 1.704) | 1.475 (1.312, 1.657) | 1.390 (1.209, 1.598) | 1.447 (1.224, 1.711) | ||
Creatinine-adjusted model | 1.611 (1.416, 1.833) | 1.544 (1.356, 1.759) | 1.443 (1.237, 1.684) | 1.530 (1.292, 1.811) | ||
TB (n = 10 556) | 1.044 (0.921, 1.183) | |||||
Volume-based model | 1.201 (1.003, 1.438) | 1.173 (0.974, 1.413) | 1.256 (1.021, 1.545) | 1.399 (1.096, 1.785) | ||
Creatinine-adjusted model | 1.241 (1.031, 1.495) | 1.211 (1.009, 1.452) | 1.301 (1.064, 1.592) | 1.456 (1.150, 1.844) | ||
ALP (n=10 564) | 1.442 (1.270, 1.638) | |||||
Volume-based model | 1.568 (1.277, 1.926) | 1.522 (1.239, 1.870) | 1.510 (1.187, 1.920) | 1.443 (1.088, 1.914) | ||
Creatinine-adjusted model | 1.804 (1.457, 2.233) | 1.738 (1.409, 2.145) | 1.728 (1.351, 2.211) | 1.629 (1.222, 2.171) |
Values are presented as odds ratio (95% confidence interval).
Model 1: Not adjusted for any covariates; Model 2: Adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI; Model 3: Adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, BMI, HBV infection, HCV infection, and heavy drinking; Model 4: Excluded HBV-infected participants, HCV-infected participants, and heavy drinkers from the original study population and adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI; Model 5: Excluded smokers and former smokers from the original study population and adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; TB, total bilirubin; ALP, alkaline phosphatase; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus.
1 The sizes of subsamples used in models 1, 2, and 3 were indicated. The number of participants used in model 4 and 5 was different as follows: for model 4, the numbers of participants used to analyze the effect of cadmium on ALT, AST, GGT, TB, and ALP were 9928, 9928, 9944, 8843, and 8847, respectively; for model 5, the numbers of participants used to analyze the effect of cadmium on ALT, AST, GGT, TB, and ALP were 6174, 6174, 6184, 5545, and 5547, respectively.
Characteristics | Mean±SD or n (%) |
---|---|
No. of participants | 11 838 |
Age (y) | 50.12±18.02 |
Sex | |
Male | 5897 (49.8) |
Female | 5941 (50.2) |
Race/ethnicity | |
Non-Hispanic White | 5532 (46.7) |
Non-Hispanic Black | 2375 (20.1) |
Hispanic | 3063 (25.9) |
Others | 868 (7.3) |
Annual family income (US$) | |
<20 000 | 3162 (26.7) |
≥20 000 | 8676 (73.3) |
Smoking status | |
Current smoker | 2500 (21.1) |
Former smoker | 3154 (26.6) |
Never smoker | 6184 (52.2) |
Alcohol consumption status | |
Heavy drinker | 1755 (14.8) |
Moderate drinker | 6581 (55.6) |
Non-drinker | 3502 (29.6) |
Physical activity | |
Yes | 5114 (43.2) |
No | 6724 (56.8) |
BMI | |
Underweight | 183 (1.5) |
Normal weight | 3252 (27.5) |
Overweight | 4134 (34.9) |
Obese | 4269 (36.1) |
HBV infection | 52 (0.4) |
HCV infection | 173 (1.5) |
Exposure or clinical variables | ALT (n = 11 818) | AST (n = 11 818) | GGT (n = 11 838) | TB (n = 10 556) | ALP (n = 10 564) |
---|---|---|---|---|---|
Corresponding liver function parameter (U/L or mg/dL) | 22.35 (8.86, 56.38) | 23.95 (12.44, 46.11) | 22.24 (6.11, 80.94) | 0.63 (0.27, 1.48) | 67.23 (36.10, 125.22) |
Urinary cadmium (μg/L) | 0.28 (0.05, 1.67) | 0.28 (0.05, 1.67) | 0.28 (0.05, 1.67) | 0.27 (0.05, 1.63) | 0.27 (0.05, 1.63) |
Creatinine-adjusted urinary cadmium (μg/g creatinine) | 0.27 (0.05, 1.39) | 0.27 (0.05, 1.39) | 0.27 (0.05, 1.40) | 0.27 (0.05, 1.37) | 0.27 (0.05, 1.37) |
Variables |
Model 1 | p-value | Model 2 | p-value | Model 3 | p-value | Model 4 | p-value | Model 5 | p-value | |
---|---|---|---|---|---|---|---|---|---|---|---|
ALT (n = 11 818) | 0.005±0.007 | 0.435 | |||||||||
Volume-based model | - | 0.049±0.008 | <0.001 | 0.042±0.008 | <0.001 | 0.035±0.008 | <0.001 | 0.059±0.010 | <0.001 | ||
Creatinine-adjusted model | - | 0.066±0.008 | <0.001 | 0.056±0.008 | <0.001 | 0.051±0.008 | <0.001 | 0.074±0.010 | <0.001 | ||
AST (n = 11 818) | 0.020±0.005 | <0.001 | |||||||||
Volume-based model | - | 0.030±0.006 | <0.001 | 0.024±0.006 | <0.001 | 0.017±0.006 | 0.009 | 0.033±0.008 | <0.001 | ||
Creatinine-adjusted model | - | 0.045±0.007 | <0.001 | 0.037±0.007 | <0.001 | 0.029±0.007 | <0.001 | 0.044±0.008 | <0.001 | ||
GGT (n = 11 838) | 0.096±0.008 | <0.001 | |||||||||
Volume-based model | - | 0.093±0.011 | <0.001 | 0.084±0.011 | <0.001 | 0.070±0.011 | <0.001 | 0.071±0.013 | <0.001 | ||
Creatinine-adjusted model | - | 0.113±0.012 | <0.001 | 0.101±0.012 | <0.001 | 0.086±0.012 | <0.001 | 0.083±0.014 | <0.001 | ||
TB (n = 10 556) | 0.007±0.008 | 0.367 | |||||||||
Volume-based model | - | 0.034±0.009 | <0.001 | 0.034±0.009 | <0.001 | 0.041±0.010 | <0.001 | 0.080±0.013 | <0.001 | ||
Creatinine-adjusted model | - | 0.040±0.009 | <0.001 | 0.040±0.009 | <0.001 | 0.047±0.010 | <0.001 | 0.085±0.013 | <0.001 | ||
ALP (n = 10 564) | 0.045±0.004 | <0.001 | |||||||||
Volume-based model | - | 0.040±0.005 | <0.001 | 0.039±0.005 | <0.001 | 0.037±0.006 | <0.001 | 0.026±0.009 | 0.004 | ||
Creatinine-adjusted model | - | 0.049±0.006 | <0.001 | 0.048±0.006 | <0.001 | 0.047±0.007 | <0.001 | 0.030±0.009 | <0.001 |
Variables |
Model 1 | Model 2 | Model 3 | Model 4 | Model 5 | |
---|---|---|---|---|---|---|
ALT (n = 11 818) | 1.138 (1.054, 1.230) | |||||
Volume-based model | 1.360 (1.210, 1.528) | 1.310 (1.163, 1.477) | 1.242 (1.090, 1.415) | 1.401 (1.181, 1.662) | ||
Creatinine-adjusted model | 1.430 (1.268, 1.614) | 1.361 (1.204, 1.539) | 1.311 (1.148, 1.496) | 1.417 (1.194, 1.681) | ||
AST (n = 11 818) | 1.179 (1.083, 1.283) | |||||
Volume-based model | 1.307 (1.149, 1.486) | 1.254 (1.096, 1.435) | 1.211 (1.042, 1.408) | 1.299 (1.095, 1.540) | ||
Creatinine-adjusted model | 1.396 (1.218, 1.601) | 1.322 (1.148, 1.522) | 1.271 (1.088, 1.485) | 1.367 (1.162, 1.609) | ||
GGT (n = 11 838) | 1.479 (1.369, 1.598) | |||||
Volume-based model | 1.520 (1.357, 1.704) | 1.475 (1.312, 1.657) | 1.390 (1.209, 1.598) | 1.447 (1.224, 1.711) | ||
Creatinine-adjusted model | 1.611 (1.416, 1.833) | 1.544 (1.356, 1.759) | 1.443 (1.237, 1.684) | 1.530 (1.292, 1.811) | ||
TB (n = 10 556) | 1.044 (0.921, 1.183) | |||||
Volume-based model | 1.201 (1.003, 1.438) | 1.173 (0.974, 1.413) | 1.256 (1.021, 1.545) | 1.399 (1.096, 1.785) | ||
Creatinine-adjusted model | 1.241 (1.031, 1.495) | 1.211 (1.009, 1.452) | 1.301 (1.064, 1.592) | 1.456 (1.150, 1.844) | ||
ALP (n=10 564) | 1.442 (1.270, 1.638) | |||||
Volume-based model | 1.568 (1.277, 1.926) | 1.522 (1.239, 1.870) | 1.510 (1.187, 1.920) | 1.443 (1.088, 1.914) | ||
Creatinine-adjusted model | 1.804 (1.457, 2.233) | 1.738 (1.409, 2.145) | 1.728 (1.351, 2.211) | 1.629 (1.222, 2.171) |
BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus; SD, standard deviation.
Values are presented as geometric mean (95% confidence interval). ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; TB, total bilirubin; ALP, alkaline phosphatase.
Values are presented as beta±standard error. Model 1: Not adjusted for any covariates; Model 2: Adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI; Model 3: Adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, BMI, HBV infection, HCV infection, and heavy drinking; Model 4: Excluded HBV-infected participants, HCV-infected participants, and heavy drinkers from the original study population and adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI; Model 5: Excluded smokers and former smokers from the original study population and adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; TB, total bilirubin; ALP, alkaline phosphatase; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus. The sizes of subsamples used in models 1, 2, and 3 were indicated. The number of participants used in model 4 and 5 was different as follows: for model 4, the numbers of participants used to analyze the effect of cadmium on ALT, AST, GGT, TB, and ALP were 9928, 9928, 9944, 8843, and 8847, respectively; for model 5, the numbers of participants used to analyze the effect of cadmium on ALT, AST, GGT, TB, and ALP were 6174, 6174, 6184, 5545, and 5547, respectively.
Values are presented as odds ratio (95% confidence interval). Model 1: Not adjusted for any covariates; Model 2: Adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI; Model 3: Adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, BMI, HBV infection, HCV infection, and heavy drinking; Model 4: Excluded HBV-infected participants, HCV-infected participants, and heavy drinkers from the original study population and adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI; Model 5: Excluded smokers and former smokers from the original study population and adjusted for age, sex, race/ethnicity, annual family income, smoking status, alcohol consumption status, physical activity, and BMI. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; TB, total bilirubin; ALP, alkaline phosphatase; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C virus. The sizes of subsamples used in models 1, 2, and 3 were indicated. The number of participants used in model 4 and 5 was different as follows: for model 4, the numbers of participants used to analyze the effect of cadmium on ALT, AST, GGT, TB, and ALP were 9928, 9928, 9944, 8843, and 8847, respectively; for model 5, the numbers of participants used to analyze the effect of cadmium on ALT, AST, GGT, TB, and ALP were 6174, 6174, 6184, 5545, and 5547, respectively.